Niagen Bioscience (NASDAQ:NAGE) Upgraded to Strong-Buy at Freedom Capital

Niagen Bioscience (NASDAQ:NAGE) was upgraded by analysts at Freedom Capital to a “strong-buy” rating in a research note issued on Monday,Zacks.com reports.

A number of other equities research analysts have also recently commented on the stock. Weiss Ratings reiterated a “hold (c)” rating on shares of Niagen Bioscience in a report on Tuesday, April 21st. HC Wainwright reaffirmed a “buy” rating on shares of Niagen Bioscience in a research report on Wednesday, July 1st. Canaccord Genuity Group cut their target price on Niagen Bioscience from $13.00 to $10.00 and set a “buy” rating on the stock in a research note on Tuesday, May 5th. Finally, Wall Street Zen cut Niagen Bioscience from a “buy” rating to a “hold” rating in a research note on Saturday, April 25th. One equities research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus target price of $10.50.

Niagen Bioscience Price Performance

Shares of Niagen Bioscience stock opened at $3.37 on Monday. Niagen Bioscience has a 1 year low of $3.17 and a 1 year high of $12.41. The firm’s 50-day moving average is $3.70 and its 200 day moving average is $4.79. The stock has a market cap of $268.39 million, a price-to-earnings ratio of 16.05 and a beta of 2.09.

Niagen Bioscience (NASDAQ:NAGE) last released its quarterly earnings data on Wednesday, May 6th. The company reported $0.07 earnings per share for the quarter, beating analysts’ consensus estimates of $0.06 by $0.01. The business had revenue of $31.47 million during the quarter. Niagen Bioscience had a net margin of 14.29% and a return on equity of 22.68%. On average, equities analysts expect that Niagen Bioscience will post 0.22 EPS for the current fiscal year.

Institutional Investors Weigh In On Niagen Bioscience

A number of hedge funds have recently added to or reduced their stakes in the stock. JPMorgan Chase & Co. bought a new position in shares of Niagen Bioscience during the 3rd quarter valued at $3,678,000. Vanguard Group Inc. bought a new stake in shares of Niagen Bioscience in the third quarter worth $37,522,000. Ameritas Investment Partners Inc. purchased a new stake in Niagen Bioscience during the third quarter valued at $45,000. Intech Investment Management LLC purchased a new stake in Niagen Bioscience during the third quarter valued at $202,000. Finally, Quantbot Technologies LP bought a new position in Niagen Bioscience in the third quarter valued at about $48,000. 15.41% of the stock is currently owned by hedge funds and other institutional investors.

Niagen Bioscience Company Profile

Niagen Bioscience, Inc is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company’s patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen. It operates through the following segments: Consumer Products, Ingredients, and Analytical Reference Standards and Services.